Minerva Neurosciences Overview
Valuation check: NERV's ROE is 1415.46%, above the Healthcare sector average of -100.59%.
Get informed when a big investor buys or sells
+ Follow1415.46%
Return on Equity measures how efficiently a company uses shareholders' equity to generate profits. A higher ROE indicates better profitability relative to equity.
Minerva Neurosciences (NERV) currently reports a ROE of 1415.46%. That is above the Healthcare sector average of -100.59%. Use the charts on this page to explore Minerva Neurosciences's ROE history and peer comparisons.
Minerva Neurosciences's ROE of 1415.46% is higher than the Healthcare sector average of -100.59%. That is roughly 1507.2% above the sector mean. A reading higher peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.
There is no universal 'good' ROE, but Minerva Neurosciences's current 1415.46% should be judged against Healthcare norms (sector average: -100.59%) and against NERV's own history. Strong, stable readings often indicate durable competitive advantage; volatile or declining ones deserve a closer look at margins and capital efficiency.
Start with the current ROE of 1415.46%, then check the historical chart for trend and the peer comparison chart for relative positioning. The Healthcare average is -100.59%. From there, open related valuation or income-statement pages for Minerva Neurosciences, and consider following NERV for alerts when major investors trade the stock.
Minerva Neurosciences is classified in the Healthcare sector. On ROE, it currently shows 1415.46% versus a sector average near -100.59%. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing NERV with unrelated industries.
